FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Multiple Violations Cited at ProRx Outsourcing Facility

FDA warns Exton, PA-based ProRx about multiple violations in its production of drugs as an outsourcing facility.

latest-news-card-1
Medical Devices

Cybersecurity Vulnerabilities in 2 Patient Monitors

An FDA safety communication warns about cybersecurity vulnerabilities in Contec and Epsimed patient monitors.

latest-news-card-1
FDA General

Committee Chair Struggles to Support Kennedy

Senate Health Education Labor & Pensions Committee chair Bill Cassidy (R-LA) says he is having a difficult time believing HHS secretary-nominee Robert...

latest-news-card-1
Human Drugs

FDA Approves Axsomes Migraine Drug

FDA approves Axsome Therapeutics Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.

latest-news-card-1
Human Drugs

FDA Clears Roche Lipoprotein (a) Assay

FDA clears a Roche 510(k) for its Tina-quant Lipoprotein (a) Gen.2 Molarity assay that measures lipoprotein (a) in nanomoles per liter.

latest-news-card-1
Medical Devices

Breakthrough Status for Meniscus Knee Implant

FDA grants OrthoPreserve a breakthrough device designation for its Defender meniscus replacement knee implant.

latest-news-card-1
Human Drugs

Orphan Drug Designation for Marsh Lymphoma Drug

FDA grants orphan drug designation to March Biosciences MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma.

latest-news-card-1
Human Drugs

Adial Finishes Alcohol Abuse Drug PK Study

Adial Pharmaceuticals reports positive results from its pharmacokinetic study of ondansetron to treat alcohol use disorder

latest-news-card-1
FDA General

Trust in Health Agencies Continues Decline: KFF

The latest Kaiser Family Foundation health information and trust tracking poll sees a continuing decline in public trust in FDA and other health agenc...

Biologics

Better Vaccine Communication Needed: Column

A MedPageToday column calls for a whole new approach to communicating about vaccines to persuade people to use them.